What's Going On With Cancer-Focused Immuneering Stock On Thursday?

Zinger Key Points
  • Immuneering says 100% suppression of acquired RAS alterations was observed in evaluable patients, supporting goal of Universal-RAS activity.
  • Initial data from multiple arms of the Phase 2a portion of Immuneering's Phase 1/2a study of IMM-1-104 is expected in 2024.

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors.

As of February 20, 2024 (N=19), patient plasma data showed IMM-1-104 at 320mg inhibiting phosphorylated extracellular signal-regulated kinase at a level of 90% or greater for 2.7 hours before returning to near-zero levels in advance of 24 hours.

IMM-1-104 at a 240mg dose achieved 90% or greater levels of pERK inhibition for 1.9 hours before returning to near-zero levels in advance of 24 hours.

Immuneering evaluated 240mg and 320mg QD as prospective doses for the Phase 2a portion of its Phase 1/2a study. The company has selected the 320mg QD as the recommended phase 2 dose.

As of February 20, 2024 (N=22), 100% of evaluable patients profiled for ctDNA treated with IMM-1-104 experienced no new acquired alterations in RAS.

Excluding two patients treated with IMM-1-104 at 160mg (which Immuneering believes to be a sub-therapeutic dose), no new acquired alterations in MAPK pathway genes were observed, suggesting that there was no mutation in the MAPK pathway that a tumor could use to evade IMM-1-104.

53% of patients had ≥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg.

Best individual lesion regressions were -35.7% at 320mg in the second-line setting (vs. -11.4% at 240mg).

Best RECIST SLD was -18.9% at 320mg in second-line setting (vs. -7.1% at 240mg).

The longest duration of therapy was 162 days (5+ months) at 240mg, with no TRAEs.

As of February 20, 2024 (N=41), IMM-1-104 has been well-tolerated, with the potential for a differentiated safety profile.

In March, Immuneering dosed the first patient in the Phase 2a portion of the Phase 1/2a trial.

Initial data from multiple arms of the Phase 2a portion of Immuneering’s Phase 1/2a study of IMM-1-104 is expected in 2024.

Price Action: IMRX shares reached as high as $7.35 during the premarket session, and are now trading 44.80% lower at $3.25 on the last check Thursday.

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefsStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...